BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 29296803)

  • 1. Targeted deep sequencing in primary myelofibrosis.
    Tefferi A; Lasho TL; Finke CM; Elala Y; Hanson CA; Ketterling RP; Gangat N; Pardanani A
    Blood Adv; 2016 Dec; 1(2):105-111. PubMed ID: 29296803
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted deep sequencing in polycythemia vera and essential thrombocythemia.
    Tefferi A; Lasho TL; Guglielmelli P; Finke CM; Rotunno G; Elala Y; Pacilli A; Hanson CA; Pancrazzi A; Ketterling RP; Mannarelli C; Barraco D; Fanelli T; Pardanani A; Gangat N; Vannucchi AM
    Blood Adv; 2016 Nov; 1(1):21-30. PubMed ID: 29296692
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Primary myelofibrosis: 2017 update on diagnosis, risk-stratification, and management.
    Tefferi A
    Am J Hematol; 2016 Dec; 91(12):1262-1271. PubMed ID: 27870387
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted next-generation sequencing in blast phase myeloproliferative neoplasms.
    Lasho TL; Mudireddy M; Finke CM; Hanson CA; Ketterling RP; Szuber N; Begna KH; Patnaik MM; Gangat N; Pardanani A; Tefferi A
    Blood Adv; 2018 Feb; 2(4):370-380. PubMed ID: 29467191
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Allogeneic stem cell transplantation in patients with myelofibrosis harboring the MPL mutation.
    Mannina D; Gagelmann N; Badbaran A; Ditschkowski M; Bogdanov R; Robin M; Cassinat B; Heuser M; Shahswar R; Thol F; Beelen D; Kröger N
    Eur J Haematol; 2019 Dec; 103(6):552-557. PubMed ID: 31446640
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The prognostic contribution of CBL, NRAS, KRAS, RUNX1, and TP53 mutations to mutation-enhanced international prognostic score systems (MIPSS70/plus/plus v2.0) for primary myelofibrosis.
    Loscocco GG; Rotunno G; Mannelli F; Coltro G; Gesullo F; Pancani F; Signori L; Maccari C; Esposito M; Paoli C; Vannucchi AM; Guglielmelli P
    Am J Hematol; 2024 Jan; 99(1):68-78. PubMed ID: 37846894
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Primary myelofibrosis: 2014 update on diagnosis, risk-stratification, and management.
    Tefferi A
    Am J Hematol; 2014 Sep; 89(9):915-25. PubMed ID: 25124313
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutations and prognosis in primary myelofibrosis.
    Vannucchi AM; Lasho TL; Guglielmelli P; Biamonte F; Pardanani A; Pereira A; Finke C; Score J; Gangat N; Mannarelli C; Ketterling RP; Rotunno G; Knudson RA; Susini MC; Laborde RR; Spolverini A; Pancrazzi A; Pieri L; Manfredini R; Tagliafico E; Zini R; Jones A; Zoi K; Reiter A; Duncombe A; Pietra D; Rumi E; Cervantes F; Barosi G; Cazzola M; Cross NC; Tefferi A
    Leukemia; 2013 Sep; 27(9):1861-9. PubMed ID: 23619563
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A compendium of cytogenetic abnormalities in myelofibrosis: molecular and phenotypic correlates in 826 patients.
    Wassie E; Finke C; Gangat N; Lasho TL; Pardanani A; Hanson CA; Ketterling RP; Tefferi A
    Br J Haematol; 2015 Apr; 169(1):71-6. PubMed ID: 25521305
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical impacts of the mutational spectrum in Japanese patients with primary myelofibrosis.
    Morishita S; Ochiai T; Misawa K; Osaga S; Inano T; Fukuda Y; Edahiro Y; Ohsaka A; Araki M; Komatsu N
    Int J Hematol; 2021 Apr; 113(4):500-507. PubMed ID: 33389584
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Somatic mutations of calreticulin in myeloproliferative neoplasms.
    Klampfl T; Gisslinger H; Harutyunyan AS; Nivarthi H; Rumi E; Milosevic JD; Them NC; Berg T; Gisslinger B; Pietra D; Chen D; Vladimer GI; Bagienski K; Milanesi C; Casetti IC; Sant'Antonio E; Ferretti V; Elena C; Schischlik F; Cleary C; Six M; Schalling M; Schönegger A; Bock C; Malcovati L; Pascutto C; Superti-Furga G; Cazzola M; Kralovics R
    N Engl J Med; 2013 Dec; 369(25):2379-90. PubMed ID: 24325356
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of genomic alterations on outcomes in myelofibrosis patients undergoing JAK1/2 inhibitor therapy.
    Spiegel JY; McNamara C; Kennedy JA; Panzarella T; Arruda A; Stockley T; Sukhai M; Thomas M; Bartoszko J; Ho J; Siddiq N; Maze D; Schimmer A; Schuh A; Sibai H; Yee K; Claudio J; Devlin R; Minden MD; Kamel-Reid S; Gupta V
    Blood Adv; 2017 Sep; 1(20):1729-1738. PubMed ID: 29296819
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Primary myelofibrosis: 2013 update on diagnosis, risk-stratification, and management.
    Tefferi A
    Am J Hematol; 2013 Feb; 88(2):141-50. PubMed ID: 23349007
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transplant Decisions in Patients with Myelofibrosis: Should Mutations Be the Judge?
    Salit RB; Deeg HJ
    Biol Blood Marrow Transplant; 2018 Apr; 24(4):649-658. PubMed ID: 29128551
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients.
    Tefferi A; Guglielmelli P; Lasho TL; Rotunno G; Finke C; Mannarelli C; Belachew AA; Pancrazzi A; Wassie EA; Ketterling RP; Hanson CA; Pardanani A; Vannucchi AM
    Leukemia; 2014 Jul; 28(7):1494-500. PubMed ID: 24496303
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular Pathogenesis and Clinical Significance of Driver Mutations in Primary Myelofibrosis: A Review.
    Alshemmari SH; Rajan R; Emadi A
    Med Princ Pract; 2016; 25(6):501-509. PubMed ID: 27756071
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic score including gene mutations in chronic myelomonocytic leukemia.
    Itzykson R; Kosmider O; Renneville A; Gelsi-Boyer V; Meggendorfer M; Morabito M; Berthon C; Adès L; Fenaux P; Beyne-Rauzy O; Vey N; Braun T; Haferlach T; Dreyfus F; Cross NC; Preudhomme C; Bernard OA; Fontenay M; Vainchenker W; Schnittger S; Birnbaum D; Droin N; Solary E
    J Clin Oncol; 2013 Jul; 31(19):2428-36. PubMed ID: 23690417
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Calreticulin mutation profile in Indian patients with primary myelofibrosis.
    Sazawal S; Singh N; Mahapatra M; Saxena R
    Hematology; 2015 Dec; 20(10):567-70. PubMed ID: 25959795
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Application of an NGS-based 28-gene panel in myeloproliferative neoplasms reveals distinct mutation patterns in essential thrombocythaemia, primary myelofibrosis and polycythaemia vera.
    Delic S; Rose D; Kern W; Nadarajah N; Haferlach C; Haferlach T; Meggendorfer M
    Br J Haematol; 2016 Nov; 175(3):419-426. PubMed ID: 27447873
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Next-Generation Sequencing Panel Test in Myeloid Neoplasms and Evaluation with the Clinical Results.
    Kahraman CY; Sincan G; Tatar A
    Eurasian J Med; 2022 Jun; 54(2):181-185. PubMed ID: 35703527
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.